GB2345058A — Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system

USPTO Abstract

A compound of the formula (1): <EMI ID=1.1 HE=30 WI=48 LX=816 LY=400 TI=CF> <PC>wherein A is <EMI ID=1.2 HE=46 WI=140 LX=288 LY=772 TI=CF> <PC>wherein R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> are independently selected from H and alkyl;<BR> wherein X is O, S, NR<SP>4</SP> or a direct bond, wherein R<SP>4</SP> is H or alkyl;<BR> wherein Z is a hydrocarbyl chain comprising from 1 to 10 carbon atoms optionally interrupted by one or more heteroatom(s) and optionally substituted by one or more oxo substituent(s);<BR> wherein q is 1, 2 or 3;<BR> wherein if q is 2 or 3, then each A can be the same or different;<BR> wherein the or each R<SP>5</SP> is independently selected from H and alkyl;<BR> wherein the or each R<SP>6</SP> is independently selected from alkyl;<BR> wherein n is 1 to 5;<BR> wherein p is 0 to 4; and<BR> wherein the sum of n and p is less than 6,<BR> or a pharmaceutically acceptable salt thereof, and the use thereof in therapy, particularly for the treatment of a condition associated with oxidative stress, such as oxidative damage of the central nervous system or an acute or chronic neurological disorder such as traumatic brain injury, spinal cord injury, cerebral tumour, subharrachnoid haemorrage/cerebral vasospasm, cerebral ischaemia, stroke (ischaemic or haemorragic), Alzheimer's disease, Huntington's Disease, Parkinson's Disease, Friedrich's ataxia, motor neuron disease or multiple sclerosis.